Adair Locke et al., 2015-06-10: Professional-society review (Anesthesia Patient Safety Foundation) setting out methylene blue's MAO-A inhibition and the serotonin-toxicity risk when it is given with SSRIs and other serotonergic drugs, with a count of published case reports.
It is a potent monoamine oxidase (MAO) inhibitor, and in combination with other serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), MB can produce serotonin toxicity in the perioperative period.
Adair Locke et al., 2015-06-10: Professional-society review (Anesthesia Patient Safety Foundation) setting out methylene blue's MAO-A inhibition and the serotonin-toxicity risk when it is given with SSRIs and other serotonergic drugs, with a count of published case reports. C7 APSF newsletter article, June 10 2015, by Adair Locke, MD. It is a clinical-use safety article by a professional safety foundation, not a position statement on consumer sales. Records 'at least 14 individual published case reports of probable or definite serotonin toxicity involving the concurrent use of serotonin reuptake inhibitors and methylene blue, 1 of which was fatal'. text_file=D_12.txt Study type: review.
